<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00665652</url>
  </required_header>
  <id_info>
    <org_study_id>RV-PN-PI-235 D0713</org_study_id>
    <nct_id>NCT00665652</nct_id>
  </id_info>
  <brief_title>Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance</brief_title>
  <acronym>MGUS</acronym>
  <official_title>A Phase II Trial of Lenalidomide as a Treatment for Neuropathy Associated With Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to learn about the effects of the drug, lenalidomide (Revlimid®),&#xD;
      on neuropathy (damage to the nerves that affect feelings and strength) associated with&#xD;
      Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening:&#xD;
&#xD;
      All subjects eligible for screening must sign an informed consent for the study prior to any&#xD;
      study related procedures.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      This is an open-label, single-institutional clinical study of lenalidomide as a treatment for&#xD;
      MGUS associated neuropathy. Eligible patients will be followed for 28 days before starting&#xD;
      study drug. Subjects who remain eligible during the 28 day pretreatment period will receive&#xD;
      lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12&#xD;
      cycles. All patients on treatment will be followed and will be included in the intention to&#xD;
      treat group. Patients will be evaluated every three months with the TNS. On-treatment&#xD;
      patients must come to clinic at least monthly for the first 3 cycles, and then can come as&#xD;
      per the schedule of study assessments only if they are on a stable dose of lenalidomide for&#xD;
      at least one cycle. Subjects will be enrolled in the study for up to 14 months.&#xD;
&#xD;
      Lenalidomide administration:&#xD;
&#xD;
      Lenalidomide is an oral medication that will be taken at approximately the same time each day&#xD;
      with or without food.&#xD;
&#xD;
      Lenalidomide capsules should be swallowed whole, and should not be broken, chewed or opened.&#xD;
&#xD;
      If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day.&#xD;
      If it is missed for the entire day, it should not be made up.&#xD;
&#xD;
      Patients who take more than the prescribed dose of lenalidomide should be instructed to seek&#xD;
      emergency medical care if needed and contact study staff immediately.&#xD;
&#xD;
      Dosing Regimen:&#xD;
&#xD;
      The planned dose of lenalidomide for investigation is 25 mg/day, orally on days 1-21 followed&#xD;
      by 7 days rest (28 day cycle). Dosing will be in the morning at approximately the same time&#xD;
      each day. The planned dose is: Plavix 75mg/day or aspirin 325mg/day.&#xD;
&#xD;
      Subjects experiencing adverse events may need study treatment modifications&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study has been suspended for slower than anticipated enrollment to date.&#xD;
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 19, 2011</completion_date>
  <primary_completion_date type="Actual">May 19, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Neuropathy Score in Subjects With MGUS Associated Neuropathy After Treatment With Lenalidomide.</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Minimum value of the Total Neuropathy Score is &quot;0&quot;, maximum value is &quot;40&quot;. A higher score represents a worsening.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Neuropathy</condition>
  <condition>Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)</condition>
  <arm_group>
    <arm_group_label>Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.</description>
    <arm_group_label>Lenalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically proven MGUS associated neuropathy with a Total Neuropathy Score (TNS) ≥5&#xD;
             (determined by exam, history and confirmatory EDX testing in association with MGUS&#xD;
             (IgM,IgG,IgA))&#xD;
&#xD;
          -  Disease duration less than or equal to 8 years&#xD;
&#xD;
          -  Able to take Plavix 75mg/day or aspirin 325 mg daily as prophylactic anticoagulation.&#xD;
             (patients currently taking warfarin with a stable INR may stay on current dose)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients previously treated with thalidomide&#xD;
&#xD;
          -  Patients previously treated with lenalidomide&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from signing the informed consent form.&#xD;
&#xD;
          -  The development of erythema nodosum if characterized by a desquamating rash while&#xD;
             taking thalidomide or similar drugs&#xD;
&#xD;
          -  Known positive for HIV or infectious hepatitis, type A, B or C&#xD;
&#xD;
          -  Medical history of deep venous thrombosis or hyper-coagulable state&#xD;
&#xD;
          -  Gastrointestinal abnormalities including: inability to take oral medication,&#xD;
             requirement for intravenous alimentation, prior surgical procedures affecting&#xD;
             absorption, or active peptic ulcer disease&#xD;
&#xD;
          -  Patients with dementia, other serious neurological diseases, uncompensated medical&#xD;
             illness, substance abuse and debilitating psychiatric illness.&#xD;
&#xD;
          -  A serious uncontrolled medical disorder or active infection that would impair the&#xD;
             patient's ability to receive study treatment. Significant cardiac disease, including&#xD;
             uncontrolled high blood pressure, unstable angina, congestive heart failure,&#xD;
             myocardial infarction within the previous 6 months or serious cardiac arrhythmias will&#xD;
             be excluded.&#xD;
&#xD;
          -  Medical conditions associated with neuropathy such as active thyroid disease, diabetes&#xD;
             mellitus, and lupus, nutritional deficiencies, malignancy, human immunodeficiency&#xD;
             virus infection, alcohol dependence, amyloidosis, or connective tissue diseases and&#xD;
             Guillain-Barre Syndrome. Medications or toxic exposures known to cause neuropathy, or&#xD;
             a family history of neuropathy will also be grounds for exclusion.&#xD;
&#xD;
          -  Pregnant or breast feeding females. (Lactating females must agree not to breast feed&#xD;
             while taking lenalidomide).&#xD;
&#xD;
          -  Subjects who are allergic to aspirin or Plavix (clopidogrel)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elijah W. Stommel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <results_first_submitted>April 30, 2018</results_first_submitted>
  <results_first_submitted_qc>September 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 11, 2018</results_first_posted>
  <last_update_submitted>September 7, 2018</last_update_submitted>
  <last_update_submitted_qc>September 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Elijah W. Stommel</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Neuropathy</keyword>
  <keyword>Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)</keyword>
  <keyword>MGUS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Paraproteinemias</mesh_term>
    <mesh_term>Monoclonal Gammopathy of Undetermined Significance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lenalidomide</title>
          <description>Lenalidomide: Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer met inclusion criteria.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lenalidomide</title>
          <description>Lenalidomide: Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Neuropathy Score in Subjects With MGUS Associated Neuropathy After Treatment With Lenalidomide.</title>
        <description>Minimum value of the Total Neuropathy Score is &quot;0&quot;, maximum value is &quot;40&quot;. A higher score represents a worsening.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>Subjects were evaluable if they were on study drug for 3 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>Lenalidomide: Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Neuropathy Score in Subjects With MGUS Associated Neuropathy After Treatment With Lenalidomide.</title>
          <description>Minimum value of the Total Neuropathy Score is &quot;0&quot;, maximum value is &quot;40&quot;. A higher score represents a worsening.</description>
          <population>Subjects were evaluable if they were on study drug for 3 months.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="-4" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Informed consent obtained through Month 14.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lenalidomide</title>
          <description>Lenalidomide: Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elijah Stommel</name_or_title>
      <organization>Dartmouth Hitchcock Medical Center</organization>
      <phone>603-650-5104</phone>
      <email>elijah.w.stommel@hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

